keyword
MENU ▼
Read by QxMD icon Read
search

HCC Recurrence

keyword
https://www.readbyqxmd.com/read/28643982/-current-surgical-treatment-for-hepatocellular-carcinoma-critical-appraisal-of-current-guidelines
#1
Daniel Clerc, Nermin Halkic, Nicolas Demartines, Emmanuel Melloul
Hepatocellular carcinoma (HCC) management has evolved in the last decades. Current available treatments include interventional radiology like radiofrequency ablation, transarterial chemoembolization or Yttrium 90 radioembolization. Surgery, when possible, has been proven to be the most effective treatment in reducing the risk of long-term local recurrence. American and European societies (AASLD, EASL, respectively) guidelines for the management of HCC endorse The Barcelona Clinic Liver Cancer (BCLC) treatment allocation system...
June 14, 2017: Revue Médicale Suisse
https://www.readbyqxmd.com/read/28643457/eradication-of-hepatitis-c-virus-profoundly-prolongs-survival-in-hepatocellular-carcinoma-patients-receiving-transarterial-chemoembolization
#2
Wei Teng, Yi-Chung Hsieh, Kar-Wai Lui, Wei-Ting Chen, Chien-Fu Hung, Chien-Hao Huang, Yi-Cheng Chen, Wen-Juei Jeng, Chen-Chun Lin, Chun-Yen Lin, Shi-Ming Lin, I-Shyan Sheen
Adjuvant pegylated interferon plus ribavirin treatment (PegIFN/RBV) reduces recurrence and prolongs survival in early stage hepatocellular carcinoma (HCC) patients with chronic hepatitis C (CHC) infection receiving resection or ablation. However, the impact of antiviral therapy in intermediate and advanced stage of CHC-HCC patients is uncertain. This study aimed to investigate the impact PegIFN/RBV treatment on recurrence free interval and survival in HCC patients receiving transarterial chemoembolization (TACE) METHODS: From 2010 to 2013, 274 CHC patients from a 1073-patients based cohort composed of freshly diagnosed HCC and receiving TACE treatment the Chang Gung Memorial Hospital, Linkou Medical Center were recruited...
June 22, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28643391/fatal-orthotopic-liver-transplant-organ-rejection-induced-by-a-checkpoint-inhibitor-in-two-patients-with-refractory-metastatic-hepatocellular-carcinoma
#3
Brian D Friend, Robert S Venick, Sue V McDiarmid, Xiaoyan Zhou, Bita Naini, Hanlin Wang, Douglas G Farmer, Ronald W Busuttil, Noah Federman
Although checkpoint inhibitor therapies have demonstrated significant efficacy in many malignancies, they have not been well studied in patients with a history of solid organ transplant. We describe two patients with recurrent, refractory, and progressive advanced fibrolamellar hepatocellular carcinoma (HCC) following orthotopic liver transplantation who received programmed cell death protein 1 (PD-1) inhibitor, nivolumab, on a patient access, off-label basis. Both rapidly developed irreversible acute liver rejection shortly after starting therapy, and ultimately died...
June 23, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28643196/genetic-variants-in-cell-death-pathway-genes-and-hbv-related-hepatocellular-carcinoma-among-a-chinese-han-population
#4
Fei Liu, Fuqiang Li, Limei Luo, Hanteng Yang, Yonggang Wei, Wentao Wang, Lvnan Yan, Tianfu Wen, Jiayin Yang, Bo Li
Cell death pathway plays an important role in apoptosis, and corruption of this signaling pathway has been shown to participate in carcinogenesis. We aimed at determining whether genetic variants in CASP8, CASP10 and CFLAR influence the development and clinical outcomes of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). A hospital-based case-control study, including 600 HCC cases and 600 HBsAg positive controls without HCC, was conducted to assess the relationship between 11 tagging SNPs in CASP8, CASP10 and CFLAR and HBV-related HCC risk and prognosis in a Chinese Han population...
June 22, 2017: Apoptosis: An International Journal on Programmed Cell Death
https://www.readbyqxmd.com/read/28643126/cancer-stem-cells-in-hepatocellular-carcinoma
#5
REVIEW
Tamer Yagci, Metin Cetin, Pelin Balcik Ercin
BACKGROUND: Hepatocellular carcinoma is one of the most common cancers and the second leading cause of cancer-related deaths worldwide. Only a small proportion of patients benefit from curative treatment and the prognosis is very poor for the majority of cases due to late presentation, resistance to chemotherapy and high recurrence rate. In recent years, progress in stem cell biology allowed us to explain that hierarchically organized cancer stem cells (CSCs) drive histological and functional heterogeneity of hematological malignancies and solid tumors...
June 23, 2017: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/28639906/preoperative-platelet-to-lymphocyte-ratio-is-a-valuable-prognostic-biomarker-in-patients-with-hepatocellular-carcinoma-undergoing-curative-liver-resection
#6
Hao-Jie Yang, Jing-Hang Jiang, Qing-An Liu, Cheng-Mao Zhou, Yang-Feng Du, Tao Wu, Neng-Zhi Chen, Bang-De Xiang
The Platelet to lymphocyte ratio (PLR) has been reported to predict prognosis of patients with hepatocellular carcinoma (HCC). This study examined the prognostic potential of stratified PLR for HCC patients undergoing curative liver resection. Medical records were retrospectively analyzed for 778 HCC patients undergoing curative liver resection at the Affiliated Tumor Hospital of Guangxi Medical University and the First People's Hospital of Changde between April 2010 and October 2013. Patients were stratified based on quintile analysis of their preoperative PLR, and patients in different quintiles were analyzed for overall survival (OS) and disease-free survival (DFS) using Kaplan-Meier analysis...
June 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28639005/central-hepatectomy-still-plays-an-important-role-in-treatment-of-early-stage-centrally-located-hepatocellular-carcinoma
#7
Chun-Han Chen, Tzu-Hao Huang, Cheng-Chih Chang, Wei-Feng Li, Ting-Lung Lin, Chih-Chi Wang
BACKGROUND: Surgical management of centrally located hepatocellular carcinoma (CL-HCC) poses a great challenge. Major hepatectomy (MH) might compromise future remnant liver volume (FRLV), while the long-term benefits of central hepatectomy (CH) had not been well demonstrated. METHODS: Consecutive patients with early-stage CL-HCC who underwent liver resection were enrolled. Fifteen patients underwent CH, while thirty-three were subjected to MH. All relevant clinicopathological variables were analyzed...
June 21, 2017: World Journal of Surgery
https://www.readbyqxmd.com/read/28638447/serum-igg4-igg-ratio-predicts-recurrence-of-patients-with-hepatocellular-carcinoma-after-curative-resection
#8
Jiong Wu, Xiao-Lu Ma, Lu Tian, Chun-Yan Zhang, Bei-Li Wang, Yu-Yi Hu, Xing-Hui Gao, Yan Zhou, Min-Na Shen, Yin-Fei Peng, Bai-Shen Pan, Jian Zhou, Jia Fan, Xin-Rong Yang, Wei Guo
Aim: IgG4 is associated with a Th1-to-Th2 switch, which plays a vital role in metastasis, in patients with malignances; thus, we aimed to investigate its clinical significance in predicting hepatocellular carcinoma (HCC) recurrence in the present study. Methods: The correlation between serum IgG4:IgG ratio and recurrence was analyzed in a cohort of 195 patients undergoing curative resection in 2012. Another 100 patients were analyzed in a prospective independent cohort during 2012-2013 to validate the value of serum IgG4...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28634055/an-insight-on-the-association-of-glycation-with-hepatocellular-carcinoma
#9
REVIEW
Nasimudeen R Jabir, Saheem Ahmad, Shams Tabrez
Hepato-cellular carcinoma (HCC) is one of the frequent cause of cancer-related death worldwide and dominant form of primary liver cancer. However, the reason behind a steady increase in the incidence of this form of cancer remains elusive. Glycation has been reported to play a significant role in the induction of several chronic diseases including cancer. Several risk factors that could induce HCC have been reported in the literature. Deciphering the complex patho-physiology associated with HCC is expected to provide new targets for the early detection, prevention, progression and recurrence...
June 17, 2017: Seminars in Cancer Biology
https://www.readbyqxmd.com/read/28633200/complete-response-of-advanced-hepatocellular-carcinoma-to-sorafenib-another-case-and-a-comprehensive-review
#10
Tae Suk Kim, Ji Hoon Kim, Baek Hui Kim, Young-Sun Lee, Yang Jae Yoo, Seong Hee Kang, Sang-June Suh, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun
Since sorafenib was introduced in 2007 for treating advanced hepatocellular carcinoma (HCC), 15 patients have achieved a complete response (CR) in advanced HCC. However, only four of these reports can be regarded as real CRs involving adequate assessments including imaging, serum tumor markers, and histologic examinations of completely resected specimens. A 54-year-old man with hepatitis C virus (HCV)-related liver cirrhosis (LC) presented to our unit. A CT scan demonstrated a 3.8-cm arterial hypervascular/portal-washout mass in the right lobe and invasion in the right portal vein...
June 20, 2017: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/28631359/management-of-pediatric-hepatocellular-carcinoma-a-multimodal-approach
#11
Mira A Kohorst, Deepti M Warad, Jane M Matsumoto, Julie K Heimbach, Mounif El-Youssef, Carola A S Arndt, Vilmarie Rodriguez, Amulya A Nageswara Rao
HCC is rare in the pediatric population, but is the second most common liver malignancy in children. Survival rates for primary unresectable HCC have been dismal. The objective of this study was to describe our experience with a multimodal approach for the management of unresectable HCC in two adolescent patients and to review the literature. Both patients are currently alive with no recurrence at 51 and 29 months post-transplant. Multimodality treatment involving chemotherapy with doxorubicin, cisplatin, and sorafenib; TACE; timely liver transplantation; and post-transplant therapy with sorafenib and mTOR inhibitors may help improve outcomes and prolong survival in pediatric patients with unresectable HCC...
June 20, 2017: Pediatric Transplantation
https://www.readbyqxmd.com/read/28628947/meta-analysis-of-determinants-of-survival-following-treatment-of-recurrent-hepatocellular-carcinoma
#12
REVIEW
S Erridge, P H Pucher, S R Markar, G Malietzis, T Athanasiou, A Darzi, M H Sodergren, L R Jiao
BACKGROUND: Intrahepatic recurrence of hepatocellular carcinoma (HCC) following resection is common. However, no current consensus guidelines exist to inform management decisions in these patients. Systematic review and meta-analysis of survival following different treatment modalities may allow improved treatment selection. This review aimed to identify the optimum treatment strategies for HCC recurrence. METHODS: A systematic review, up to September 2016, was conducted in accordance with MOOSE guidelines...
June 19, 2017: British Journal of Surgery
https://www.readbyqxmd.com/read/28628729/pre-and-post-operative-hbsag-levels-may-predict-recurrence-and-survival-after-curative-resection-in-patients-with-hbv-associated-hepatocellular-carcinoma
#13
Jing-Feng Qiu, Jia-Zhou Ye, Xu-Zhuo Feng, Ya-Peng Qi, Liang Ma, Wei-Ping Yuan, Jian-Hong Zhong, Zhi-Ming Zhang, Bang-De Xiang, Le-Qun Li
PURPOSE: To investigate pre- and post-operative levels of HBsAg influence prognosis of patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) after curative resection. METHODS: Medical records were retrospectively analyzed for 881 patients with HBV-related HCC treated by curative resection. Patients were classified as having high or low serum HBsAg levels (≥200 or <200 ng/mL) pre- or post-operatively. RESULTS: OS and RFS were better for patients with low pre-operative serum levels of HBsAg than for those with high levels...
June 19, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28628564/risk-of-post-transplant-hepatocellular-carcinoma-recurrence-is-higher-in-recipients-of-livers-from-male-than-female-living-donors
#14
Sangbin Han, Ju Dong Yang, Dong Hyun Sinn, Jong Man Kim, Gyu Sung Choi, Gangha Jung, Joong Hyun Ahn, Seonwoo Kim, Justin S Ko, Mi Sook Gwak, Choon Hyuck D Kwon, Michael D Leise, Geum-Youn Gwak, Julie K Heimbach, Gaab Soo Kim
OBJECTIVE: To evaluate the relationship between donor sex and hepatocellular carcinoma (HCC) recurrence after living donor liver transplantation. BACKGROUND: HCC shows a male predominance in incidence and recurrence after tumor resection due to sex differences in hepatic sex hormone receptors. There have been no studies evaluating the importance of donor sex on post-transplant HCC recurrence. METHODS: Of 384 recipients of livers, from living donors, for HCC: 104/120 who received grafts from female donors were matched with 246/264 who received grafts from male donors using propensity score matching, with an unfixed matching ratio based on factors like tumor biology...
June 16, 2017: Annals of Surgery
https://www.readbyqxmd.com/read/28627363/effect-of-interferon-based-and-free-therapy-on-early-occurrence-and-recurrence-of-hepatocellular-carcinoma-in-chronic-hepatitis-c
#15
Hiroko Nagata, Mina Nakagawa, Yasuhiro Asahina, Ayako Sato, Yu Asano, Tomoyuki Tsunoda, Masato Miyoshi, Shun Kaneko, Satoshi Otani, Fukiko Kawai-Kitahata, Miyako Murakawa, Sayuri Nitta, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Toshihiko Nouchi, Hideki Sakai, Makoto Tomita, Mamoru Watanabe
BACKGROUND AND AIMS: Although treatment for hepatitis C virus has dramatically improved by the development of direct-acting antiviral agents (DAAs), whether interferon (IFN)-free therapy reduces hepatocarcinogenesis in an equivalent manner to IFN-based therapy remains controversial. The aims of this study were to evaluate the occurrence and recurrence of hepatocellular carcinoma (HCC) in chronic hepatitis C (CHC) patients treated with DAAs and to identify biomarkers of HCC development after antiviral treatment...
June 13, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28626210/clinical-correspondence-to-hepatocellular-carcinoma-related-lesions-with-atypical-radiological-pattern
#16
Tokio Higaki, Yutaka Midorikawa, Yosuke Nakashima, Hisashi Nakayama, Shunichi Matsuoka, Mitsuhiko Moriyama, Masahiko Sugitani, Tadatoshi Takayama
In patients at risk of hepatocarcinogenesis, tumors are frequently detected with atypical radiological patterns related to hepatocellular carcinoma (HCC) on imaging studies. Despite their high potential for malignancy, whether to resect such lesions immediately is controversial. Based on histological findings, patients with non-enhanced tumors or enhanced tumors without washout were divided into two groups: those with tumors that should be treated containing well, moderately, and poorly differentiated HCC (Group 1), and those that can be observed containing early HCC, hepatocellular adenoma, focal nodular hyperplasia, dysplastic nodules, and regenerative nodules (Group 2), and we elucidated the clinical correspondence to these tumors...
June 18, 2017: Bioscience Trends
https://www.readbyqxmd.com/read/28625558/irregular-defects-in-hepatocellular-carcinomas-during-the-kupffer-phase-of-contrast-enhanced-ultrasonography-with-perfluorobutane-microbubbles-pathological-features-and-metastatic-recurrence-after-surgical-resection
#17
Junya Nuta, Naoki Shingaki, Yoshiyuki Ida, Ryo Shimizu, Shinya Hayami, Masaki Ueno, Kazuhiro Fukatsu, Masahiro Itonaga, Takeichi Yoshida, Yoshimasa Maeda, Kosaku Moribata, Hisanobu Deguchi, Takao Maekita, Mikitaka Iguchi, Jun Kato, Hiroki Yamaue, Hideyuki Tamai
The present study aimed to elucidate the association between post-vascular-phase (Kupffer-phase) images from contrast-enhanced ultrasonography (CEUS) with perfluorobutane microbubbles and metastatic recurrences after the resection of hepatocellular carcinoma (HCC). The study examined 73 patients with solitary HCC ≤5 cm in diameter who underwent CEUS before resection. HCC was defined as irregular type (including an irregular defect on Kupffer-phase images) or non-irregular type. Intrahepatic metastatic recurrence was defined as >3 intrahepatic recurrences...
June 15, 2017: Ultrasound in Medicine & Biology
https://www.readbyqxmd.com/read/28623296/iodine-125-brachytherapy-prophylaxis-after-radiofrequency-ablation-cannot-benefit-patients-in-high-risk-of-locoregional-hepatocellular-carcinoma-recurrence
#18
Jian-Fei Tu, Ya-Hui Ding, Li Chen, Xi-Hui Ying, Deng-Ke Zhang, Fa-Zong Wu, Zhong-Wei Zhao, Jian-Song Ji, Wang-Gang Zhang, Hai Zou
This study evaluated if iodine-125 brachytherapy prophylaxis after radiofrequency ablation (RFA) prolongs time to recurrence (TTR) and overall survival (OS) of patients in high risk of locoregional hepatocellular carcinoma (HCC) recurrence. 116 patients with total tumor necrosis after RFA were divided into iodine-125 brachytherapy prophylaxis treatment group and control group. The primary endpoint was TTR, and secondary endpoints were OS and treatment-related adverse events. There were no significant differences among the baseline characteristics of two subgroups patients...
June 16, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28617830/on-treatment-decrease-of-nkg2d-correlates-to-early-emergence-of-clinically-evident-hepatocellular-carcinoma-after-interferon-free-therapy-for-chronic-hepatitis-c
#19
Po-Sung Chu, Nobuhiro Nakamoto, Nobuhito Taniki, Keisuke Ojiro, Takeru Amiya, Yuko Makita, Hiroko Murata, Akihiro Yamaguchi, Shunsuke Shiba, Rei Miyake, Tadashi Katayama, Aya Ugamura, Akihiko Ikura, Karin Takeda, Hirotoshi Ebinuma, Hidetsugu Saito, Takanori Kanai
BACKGROUND AND AIMS: Interferon (IFN)- free direct antiviral agents (DAAs) with rapid HCV eradication might evoke immunological reconstitutions, and some early recurrences of HCC after IFN-free DAAs have been reported. This study aimed to investigate whether natural killer group 2, member D (NKG2D) predicts early emergence of HCC after IFN-free DAAs. METHODS: We conducted a clinical practice-based observational study of 101 patients infected with genotype 1 HCV who received IFN-free (DAAs), and stratified them into those who did or did not develop early (i...
2017: PloS One
https://www.readbyqxmd.com/read/28615696/intraoperative-imaging-of-hepatic-cancers-using-%C3%AE-glutamyltranspeptidase-specific-fluorophore-enabling-real-time-identification-and-estimation-of-recurrence
#20
Yoichi Miyata, Takeaki Ishizawa, Mako Kamiya, Suguru Yamashita, Kiyoshi Hasegawa, Aya Ushiku, Junji Shibahara, Masashi Fukayama, Yasuteru Urano, Norihiro Kokudo
γ-Glutamyltranspeptidase (GGT) is upregulated in a variety of human cancers including primary and secondary hepatic tumors. This motivated us to use γ-glutamyl hydroxymethyl rhodamine green (gGlu-HMRG), a novel fluorophore emitting light at around 520 nm following enzymatic reaction with GGT, as a tool for the intraoperative identification of hepatic tumors. gGlu-HMRG was topically applied to 103 freshly resected hepatic specimens. Fluorescence imaging using gGlu-HMRG identified hepatic tumors with the sensitivity/specificity of 48%/96% for hepatocellular carcinoma, 100%/100% for intrahepatic cholangiocarcinoma, and 87%/100% for colorectal liver metastasis...
June 14, 2017: Scientific Reports
keyword
keyword
78537
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"